期刊
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
卷 20, 期 4, 页码 299-308出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/cap.2010.0040
关键词
-
资金
- Boehringer Ingelheim
- Otsuka
- Eli Lilly
- Pediatric Obsessive-compulsive and Related Disorders fund
- Eli Lilly and Co.
- Forest Laboratories
- Glaxo-SmithKline
- Pfizer
- Ethel DuPont Warren Fellowship
- American Academy of Child and Adolescent Psychiatry [2005]
- National Institute of Mental Health
- McNeil Pediatrics
- SynerMed Communications
- Bristol Myers Squibb
- Glaxo Smith Kline
- Shire
- Johnson Johnson
- Merck
- Cephlon
- McNeil
- Eli-Lily
- Abbott
- Novartis
- Organon
- Takeda
- New River Pharmaceuticals
Recently, research in pediatric obsessive-compulsive disorder (OCD) has expanded to include large family genetic studies, elaboration of phenotypic dimensions, description of co-morbid disorders and their moderating effects on treatment response and outcome, research on immune-based neuropsychiatric causes, randomized controlled trials of selective serotonin re-uptake inhibitors (SSRIs), randomized controlled trials of cognitive behavioral therapy (CBT), comparative treatment trials; new approaches in behavior therapy, and increased awareness of newer approaches to treatment. The purpose of this article is to review assessment and treatment strategies to include current advances in research.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据